ORGANOGENESIS HOLDINGS INC. Cost of Revenue
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Cost of Revenue of $23.72 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2025-05-08
- ORGANOGENESIS HOLDINGS INC. cost of revenue for the quarter ending 2025-03-31 was $23.72M, a 17.33% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. cost of revenue for the quarter ending 2024-12-31 was $31.05M, a 11.82% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. cost of revenue for the quarter ending 2024-09-30 was $26.80M, a 3.90% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. cost of revenue for the quarter ending 2024-06-30 was $29.20M, a 10.95% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. cost of revenue for fiscal 2024 was $115.74M, a 8.70% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. cost of revenue for fiscal 2023 was $106.48M, a 1.39% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. cost of revenue for fiscal 2022 was $105.02M, a 8.04% decline from fiscal 2021.
- ORGANOGENESIS HOLDINGS INC. cost of revenue for fiscal 2021 was $114.20M, a 30.78% increase from fiscal 2020.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2025-03-31 | $23.72M 10-Q · filed 2025-05-08 | $54.77M derived: sum of 2 quarters · filed 2025-05-08 | $81.57M derived: sum of 3 quarters · filed 2025-05-08 | $110.77M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | $31.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $57.85M derived: sum of 2 quarters · filed 2025-02-27 | $87.05M derived: sum of 3 quarters · filed 2025-02-27 | $115.74M 10-K · filed 2025-02-27 |
| 2024-09-30 | $26.80M 10-Q · filed 2024-11-12 | $55.99M derived: sum of 2 quarters · filed 2024-11-12 | $84.69M 10-Q · filed 2024-11-12 | $112.46M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-06-30 | $29.20M 10-Q · filed 2024-08-08 | $57.89M 10-Q · filed 2024-08-08 | $85.66M derived: sum of 3 quarters · filed 2025-05-08 | $111.45M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-03-31 | $28.70M 10-Q · filed 2025-05-08 | $56.47M derived: sum of 2 quarters · filed 2025-05-08 | $82.25M derived: sum of 3 quarters · filed 2025-05-08 | $108.57M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $27.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $53.56M derived: sum of 2 quarters · filed 2025-02-27 | $79.87M derived: sum of 3 quarters · filed 2025-02-27 | $106.48M 10-K · filed 2025-02-27 |
| 2023-09-30 | $25.79M 10-Q · filed 2024-11-12 | $52.10M derived: sum of 2 quarters · filed 2024-11-12 | $78.71M 10-Q · filed 2024-11-12 | $105.82M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $26.32M 10-Q · filed 2024-08-08 | $52.92M 10-Q · filed 2024-08-08 | $80.03M derived: sum of 3 quarters · filed 2025-02-27 | $106.21M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $26.61M 10-Q · filed 2024-05-09 | $53.72M derived: sum of 2 quarters · filed 2025-02-27 | $79.89M derived: sum of 3 quarters · filed 2025-02-27 | $106.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $27.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $53.29M derived: sum of 2 quarters · filed 2025-02-27 | $79.94M derived: sum of 3 quarters · filed 2025-02-27 | $105.02M 10-K · filed 2025-02-27 |
| 2022-09-30 | $26.18M 10-Q · filed 2023-11-09 | $52.83M derived: sum of 2 quarters · filed 2023-11-09 | $77.91M 10-Q · filed 2023-11-09 | $110.51M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $26.65M 10-Q · filed 2023-08-09 | $51.73M 10-Q · filed 2023-08-09 | $84.33M derived: sum of 3 quarters · filed 2024-02-29 | $110.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $25.08M 10-Q · filed 2023-05-10 | $57.68M derived: sum of 2 quarters · filed 2024-02-29 | $83.84M derived: sum of 3 quarters · filed 2024-02-29 | $113.78M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $32.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $58.76M derived: sum of 2 quarters · filed 2024-02-29 | $88.70M derived: sum of 3 quarters · filed 2024-02-29 | $114.20M 10-K · filed 2024-02-29 |
| 2021-09-30 | $26.17M 10-Q · filed 2022-11-09 | $56.11M derived: sum of 2 quarters · filed 2022-11-09 | $81.60M 10-Q · filed 2022-11-09 | $107.12M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $29.94M 10-Q · filed 2022-08-09 | $55.44M 10-Q · filed 2022-08-09 | $80.95M derived: sum of 3 quarters · filed 2023-03-01 | $103.92M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $25.50M 10-Q · filed 2022-05-10 | $51.02M derived: sum of 2 quarters · filed 2023-03-01 | $73.98M derived: sum of 3 quarters · filed 2023-03-01 | $94.02M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $25.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $48.48M derived: sum of 2 quarters · filed 2023-03-01 | $68.53M derived: sum of 3 quarters · filed 2023-03-01 | $87.32M 10-K · filed 2023-03-01 |
| 2020-09-30 | $22.96M 10-Q · filed 2021-11-09 | $43.01M derived: sum of 2 quarters · filed 2021-11-09 | $61.80M 10-Q · filed 2021-11-09 | $82.19M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $20.04M 10-Q · filed 2021-08-09 | $38.84M 10-Q · filed 2021-08-09 | $59.23M derived: sum of 3 quarters · filed 2022-03-01 | $78.36M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $18.79M 10-Q · filed 2021-05-11 | $39.18M derived: sum of 2 quarters · filed 2022-03-01 | $58.31M derived: sum of 3 quarters · filed 2022-03-01 | $77.76M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $20.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $39.52M derived: sum of 2 quarters · filed 2022-03-01 | $58.97M derived: sum of 3 quarters · filed 2022-03-01 | $75.95M 10-K · filed 2022-03-01 |
| 2019-09-30 | $19.13M 10-Q · filed 2020-11-09 | $38.58M derived: sum of 2 quarters · filed 2020-11-09 | $55.56M 10-Q · filed 2020-11-09 | $73.07M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $19.45M 10-Q · filed 2020-08-10 | $36.43M 10-Q · filed 2020-08-10 | $53.94M derived: sum of 3 quarters · filed 2020-08-10 | $73.41M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $16.98M 10-Q · filed 2020-05-11 | $34.49M derived: sum of 2 quarters · filed 2020-05-11 | $53.97M derived: sum of 3 quarters · filed 2020-05-11 | $71.27M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $17.51M 10-K · filed 2019-03-18 | $36.99M derived: sum of 2 quarters · filed 2019-11-12 | $54.29M derived: sum of 3 quarters · filed 2019-11-12 | $68.81M 10-K · filed 2021-03-16 |
| 2018-09-30 | $19.48M 10-Q · filed 2019-11-12 | $36.78M derived: sum of 2 quarters · filed 2019-11-12 | $51.30M 10-Q · filed 2019-11-12 | $67.72M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $17.30M 10-Q · filed 2019-08-09 | $31.82M 10-Q · filed 2019-08-09 | $48.24M derived: sum of 3 quarters · filed 2019-08-09 | $64.33M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $14.52M 10-Q · filed 2019-05-10 | $30.94M derived: sum of 2 quarters · filed 2019-05-10 | $47.03M derived: sum of 3 quarters · filed 2019-05-10 | $62.44M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | $16.42M 10-K · filed 2019-03-18 | $32.51M derived: sum of 2 quarters · filed 2019-03-18 | $47.91M derived: sum of 3 quarters · filed 2019-03-18 | $61.22M 10-K · filed 2020-03-09 |
| 2017-09-30 | $16.09M 10-K · filed 2019-03-18 | $31.49M derived: sum of 2 quarters · filed 2019-03-18 | $44.80M derived: sum of 3 quarters · filed 2019-03-18 | |
| 2017-06-30 | $15.41M 10-K · filed 2019-03-18 | $28.71M derived: sum of 2 quarters · filed 2019-03-18 | ||
| 2017-03-31 | $13.30M 10-K · filed 2019-03-18 | |||
| 2016-12-31 | $48.20M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |